[Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].

about

Electroacupuncture Promotes Remyelination after Cuprizone Treatment by Enhancing Myelin Debris Clearance.

P2860

Q37574779-CC6905FB-0E6C-4FCF-8D85-ABAB4F2298A3

P2860

[Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].

Item

http://www.wikidata.org/entity/Q41102105

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

[Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].

@en

type

Item

label

[Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].

@en

prefLabel

[Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].

@en

P1476

[Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].

@en

P2093

A Winkelmann

http://www.w3.org/2001/XMLSchema#string

E C Reisinger

http://www.w3.org/2001/XMLSchema#string

H-P Hartung

http://www.w3.org/2001/XMLSchema#string

M Löbermann

http://www.w3.org/2001/XMLSchema#string

U K Zettl

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use

Immune System Involvement in the Pathogenesis of JC Virus Induced PML: What is Learned from Studies of Patients with Underlying Diseases and Therapies as Risk Factors

Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

The human polyomavirus, JCV, uses serotonin receptors to infect cells

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.

P2888

s00115-015-4388-4

P304

971-977

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00115-015-4388-4

http://www.w3.org/2001/XMLSchema#string

P407

Af-Jarmal

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26187545

http://www.w3.org/2001/XMLSchema#string

[Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].

about

P2860

P2860

[Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P698